Medicenna finalizes terms for public offering at $0.50 per unit

Medicenna Therapeutics Corp. (TSX: MDNA) announced it has finalized terms for its previously announced public offering of securities. The clinical-stage immunotherapy company will offer units at $0.50 each, with each unit consisting of one common share and half of one warrant.

Each warrant allows the holder to purchase one common share at $0.65 until three years after the offering closes. Bloom Burton Securities Inc. is serving as sole agent for the offering.

The offering is expected to close around May 27, 2026, pending regulatory and stock exchange approvals. Medicenna plans to use proceeds primarily for clinical and regulatory development of its lead programs MDNA11 and MDNA113, working capital, and general corporate purposes.

The offering will be conducted through a prospectus supplement to the company's existing base shelf prospectus dated June 4, 2025, filed in British Columbia, Alberta and Ontario. Units may also be offered in other jurisdictions outside Canada where permitted.

Medicenna develops immunotherapy treatments targeting cancer and autoimmune diseases, focusing on IL-2, IL-4 and IL-13 Superkines. The company's MDNA11 is a next-generation IL-2 designed to preferentially stimulate cancer-fighting immune cells, while MDNA113 is a bifunctional treatment for solid tumors.

The securities have not been registered under U.S. securities laws and may not be offered or sold in the United States except under applicable exemptions. The information is based on a company press release.

You May Also Be Interested In

• Triumph Gold announces $5.4 million private placement
• First Advantage to join S&P SmallCap 600, replacing Kennedy-Wilson
• Cosmos Health signs letter of intent to acquire Doc Pharma for $24M